Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial

Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial effects in schizophrenia regarding their prominent anti-inflammatory properties. Objectives: This study was designed to evaluate the effects of simvastatin on schizophrenia symptoms. Patients and Met...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Somaieh Ashrafi, Seyyed Mohammad Ghaffari, Hatam Boostani, Somaieh Raz, Negar Ebadi, Zahra Ashrafi, Pedram Nazari
Formato:	article
Lenguaje:	EN
Publicado:	Society of Diabetic Nephropathy Prevention 2022
Materias:	schizophrenia negative symptoms simvastatin Specialties of internal medicine RC581-951 Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/8efc2929aca04a72b6e2ba29948bfbdb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8efc2929aca04a72b6e2ba29948bfbdb
record_format	dspace
spelling	oai:doaj.org-article:8efc2929aca04a72b6e2ba29948bfbdb2021-11-16T10:42:13ZAdjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial2476-393410.34172/jpe.2022.02https://doaj.org/article/8efc2929aca04a72b6e2ba29948bfbdb2022-01-01T00:00:00Zhttps://jprevepi.com/PDF/jpe-7-e02.pdfhttps://doaj.org/toc/2476-3934Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial effects in schizophrenia regarding their prominent anti-inflammatory properties. Objectives: This study was designed to evaluate the effects of simvastatin on schizophrenia symptoms. Patients and Methods: In a double-blinded randomized clinical trial, 40 hospitalized schizophrenia patients (according to the DSM-IV-TR criteria) were studied for 6 weeks. One group of the patients (n=20) received simvastatin (with the dose of 40 mg/d) and the other group received (n=20) placebo. The patients were evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia symptoms. Data were analyzed with mixed model repeated measure ANOVA, t test, and χ2 test or Fischer’s exact test by SPSS software. The significant cutoff was considered at P<0.05. Results: The mean age of the patients was 34.05±9.74 years and 50% of them were men. There was not a significant difference between the two groups regarding negative symptoms reduction. Conclusion: Our study demonstrated that adding simvastatin on atypical antipsychotic treatment had no significant beneficial effects on the negative and positive symptoms in patients with schizophrenia disorder. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT2017052034046N1; https://en.irct.ir/trial/26134, ethical code; ETH-457).Somaieh AshrafiSeyyed Mohammad GhaffariHatam BoostaniSomaieh RazNegar EbadiZahra AshrafiPedram NazariSociety of Diabetic Nephropathy Preventionarticleschizophrenianegative symptomssimvastatinSpecialties of internal medicineRC581-951Infectious and parasitic diseasesRC109-216ENJournal of Preventive Epidemiology, Vol 7, Iss 1, Pp e02-e02 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia negative symptoms simvastatin Specialties of internal medicine RC581-951 Infectious and parasitic diseases RC109-216
spellingShingle	schizophrenia negative symptoms simvastatin Specialties of internal medicine RC581-951 Infectious and parasitic diseases RC109-216 Somaieh Ashrafi Seyyed Mohammad Ghaffari Hatam Boostani Somaieh Raz Negar Ebadi Zahra Ashrafi Pedram Nazari Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
description	Introduction: Statins such as simvastatin are recently introduced as agents that may have beneficial effects in schizophrenia regarding their prominent anti-inflammatory properties. Objectives: This study was designed to evaluate the effects of simvastatin on schizophrenia symptoms. Patients and Methods: In a double-blinded randomized clinical trial, 40 hospitalized schizophrenia patients (according to the DSM-IV-TR criteria) were studied for 6 weeks. One group of the patients (n=20) received simvastatin (with the dose of 40 mg/d) and the other group received (n=20) placebo. The patients were evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia symptoms. Data were analyzed with mixed model repeated measure ANOVA, t test, and χ2 test or Fischer’s exact test by SPSS software. The significant cutoff was considered at P<0.05. Results: The mean age of the patients was 34.05±9.74 years and 50% of them were men. There was not a significant difference between the two groups regarding negative symptoms reduction. Conclusion: Our study demonstrated that adding simvastatin on atypical antipsychotic treatment had no significant beneficial effects on the negative and positive symptoms in patients with schizophrenia disorder. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT2017052034046N1; https://en.irct.ir/trial/26134, ethical code; ETH-457).
format	article
author	Somaieh Ashrafi Seyyed Mohammad Ghaffari Hatam Boostani Somaieh Raz Negar Ebadi Zahra Ashrafi Pedram Nazari
author_facet	Somaieh Ashrafi Seyyed Mohammad Ghaffari Hatam Boostani Somaieh Raz Negar Ebadi Zahra Ashrafi Pedram Nazari
author_sort	Somaieh Ashrafi
title	Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
title_short	Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
title_full	Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
title_fullStr	Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
title_full_unstemmed	Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
title_sort	adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
publisher	Society of Diabetic Nephropathy Prevention
publishDate	2022
url	https://doaj.org/article/8efc2929aca04a72b6e2ba29948bfbdb
work_keys_str_mv	AT somaiehashrafi adjunctivesimvastatintreatmentinschizophreniapatientsadoubleblindrandomizedandplacebocontrolledtrial AT seyyedmohammadghaffari adjunctivesimvastatintreatmentinschizophreniapatientsadoubleblindrandomizedandplacebocontrolledtrial AT hatamboostani adjunctivesimvastatintreatmentinschizophreniapatientsadoubleblindrandomizedandplacebocontrolledtrial AT somaiehraz adjunctivesimvastatintreatmentinschizophreniapatientsadoubleblindrandomizedandplacebocontrolledtrial AT negarebadi adjunctivesimvastatintreatmentinschizophreniapatientsadoubleblindrandomizedandplacebocontrolledtrial AT zahraashrafi adjunctivesimvastatintreatmentinschizophreniapatientsadoubleblindrandomizedandplacebocontrolledtrial AT pedramnazari adjunctivesimvastatintreatmentinschizophreniapatientsadoubleblindrandomizedandplacebocontrolledtrial
_version_	1718426561400537088

Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial

Ejemplares similares